media – Page 22 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Operating income of 3.07 billion yuan in 2024, a year-on-year increase of 13.32%

The 2024 annual report recently released by Ruipu Bio shows that the company adheres to technological innovation and strategic layout, and achieves operating income of 3.07 billion yuan, a year-on-year increase of 13.32%; net profit attributable to shareholders of listed companies is 301 million yuan; it plans to pay 3 yuan (including tax) for every 10 shares. In 2024, the company invested 238 million yuan in research and development, accounting for 7.76% of operating income, and added 10 new veterinary drug registration certificates and 29 authorized patents. In the field of biological products, cutting-edge technologies such as mRNA technology platform and recombinant duck plague virus vector vaccine have made breakthroughs. Among them, the independently developed cat triple vaccine “Ruimiaoshu” has become the first local listed product. The enrofloxacin hydrochloride pellet coating preparation developed by the Drug Research Institute reduces the cost of medication by 25%-50%, which is highly recognized by ...
- Source: drugdu
- 88
- April 14, 2025
CanSino Biologics and Jiankai Technology have a strategic partnership to explore new mRNA vaccine tumor immunity solutions

On April 9, according to the official microblog of CanSino Biologics, CanSino Biologics (Shanghai) Co., Ltd., a subsidiary of CanSino Biologics, and Tianjin Jiankai Technology Co., Ltd. (hereinafter referred to as “Jiankai Technology”), a wholly-owned subsidiary of Jiankai Technology, recently signed a cooperative development agreement. The two parties will jointly promote the clinical research project of mRNA vaccines for the treatment of glioblastoma (GBM), and it is expected that the first patient will be dosed this year. https://finance.eastmoney.com/a/202504093371737123.html
- Source: drugdu
- 74
- April 14, 2025
Products will not be easily replaced, and the impact of tariffs is limited.

On April 8, local time, US President Trump delivered a speech saying that the United States will impose tariffs on drugs. This news has once again attracted market attention to pharmaceutical companies that were “exempted” in the previous round of tariff increases. From the market reaction on the 9th, the decline of individual stocks in the API sector was the largest. Data shows that 90% of active pharmaceutical ingredients (API) in the US market rely on imports, of which 60% come from China. In the short term, API companies that rely on US export business may be affected by the tax increase, but in the long term, the tax increase on imported APIs may cause a surge in the cost of US pharmaceutical research and development and manufacturing. Industry insiders believe that US tariffs mainly have a certain impact on the low-end pharmaceutical industry, and have little impact on the ...
- Source: drugdu
- 129
- April 14, 2025
【EXPERT Q&A】Why is it difficult for generic drugs to reach the level of original drugs?

Drugdu.com expert’s response: The reasons why generic drugs often struggle to fully match the quality of brand-name (originator) drugs involve multiple aspects, primarily including differences in the research and development (R&D) process, manufacturing techniques, quality control, clinical trials, and patent/regulatory factors. Below is a detailed analysis: I. Differences in the R&D Process Lengthy R&D Timeline for Originator Drugs: Developing an originator drug from laboratory research to market approval typically takes 10–15 years and costs billions of dollars, involving rigorous clinical trials to verify safety and efficacy. Different R&D Pathway for Generic Drugs: Generic drugs do not need to replicate the pre-clinical studies or clinical trials of originator drugs; they only need to demonstrate bioequivalence (similar absorption rate and extent in the body). However, this “equivalence” does not equate to “identity,” and subtle differences may exist in drug metabolism and pharmacodynamics. II. Manufacturing Techniques and Quality Control Complexity of Manufacturing Processes: The ...
- Source: drugdu
- 110
- April 14, 2025
The United States may impose tariffs on drug imports. Many pharmaceutical companies responded with “close attention”

According to CCTV News, on April 8, there was news that the United States would impose tariffs on drugs. It is understood that the broad tariffs on US imports announced last week did not involve drugs, but at that time, it was reported that drugs would face separate tariffs. Pharmaceutical companies such as Hanyu Pharmaceutical, Kelun Pharmaceutical, and Tonghua Dongbao responded. Hanyu Pharmaceutical responded on April 9: “The company’s current products sold to the United States are mainly liraglutide and some raw materials. We and our partners are closely following the relevant developments. The relevant response needs to be studied after the specific situation of the US drug tariffs is clarified. The company has also been planning to expand into the European or Southeast Asian markets to reduce its dependence on the US market.” Kelun Pharmaceutical’s Securities Department responded: “We have just seen this news. The company’s relevant departments are ...
- Source: drugdu
- 112
- April 11, 2025
The United States will impose tariffs on drugs

On April 8, local time, US President Trump gave a speech saying that the United States will impose tariffs on drugs. Trump said that the United States does not produce its own drugs and other products that improve health. The price the United States pays for drugs is often many times higher than that of countries that produce drugs. Trump believes that once tariffs are imposed on drugs, pharmaceutical companies will open factories in the United States because the United States is the “largest market.” Last week, Trump announced a wide range of tariffs on US imports that did not involve drugs, but he said that drugs would face separate taxes. European pharmaceutical companies have warned in a meeting with the President of the European Commission on the 8th that US tariffs will accelerate the trend of the industry shifting from Europe to the United States. The pharmaceutical industry trade ...
- Source: drugdu
- 103
- April 11, 2025
Zhifei Biotech’s bivalent dysentery vaccine is ready to start enrolling subjects

On April 8, Zhifei Biotech (300122) issued an announcement that it was recently learned that the bivalent dysentery conjugate vaccine developed by the company’s wholly-owned subsidiary Zhifei Green Bamboo has obtained the Phase III clinical trial approval from the Bangladesh Drug Administration and is ready to start enrolling subjects. The vaccine is designed to prevent bacterial dysentery caused by Shigella flexneri and Shigella sonnei, which affects 164.7 million people worldwide each year, especially in developing countries and children under 5 years old. In the first three quarters of 2024, Zhifei Biotech achieved revenue of 22.786 billion yuan and net profit attributable to the parent of 2.151 billion yuan. https://finance.eastmoney.com/a/202504083369655980.html
- Source: drugdu
- 111
- April 11, 2025
The oral vaccine developed by Kangtai Biological and its subsidiaries has started Phase III clinical trials

On April 9, Kangtai Biological (300601) issued an announcement, announcing that the oral pentavalent reassortant rotavirus attenuated live vaccine (Vero cells) developed by it and its wholly-owned subsidiary Minhai Biological has completed the preparations for Phase III clinical trials and successfully completed the first subject enrollment. This marks that the product development has made phased progress and further promoted the company’s vaccine development process. This Phase III clinical trial adopts a multi-center, randomized, double-blind, placebo-controlled design to evaluate the protective efficacy, safety and immunogenicity of the vaccine in Chinese infants and young children. https://finance.eastmoney.com/a/202504093371486634.html
- Source: drugdu
- 106
- April 11, 2025
【EXPERT Q&A】Has stem cell therapy entered the clinical stage?

Drugdu.com expert’s response: Stem cell therapy has entered the clinical treatment stage and is continuously advancing globally, with multiple countries approving related therapies for specific diseases, while numerous clinical trials are underway to verify their safety and efficacy. I. Approved Stem Cell Therapies United States: In 2010, the FDA approved Prochymal® (allogeneic bone marrow mesenchymal stem cells) for the treatment of pediatric graft-versus-host disease (GvHD), marking the world’s first approved stem cell drug. European Union: In 2015, the EU approved Holoclar® (autologous limbal stem cells) for the treatment of severe limbal stem cell deficiency. Japan: In 2018, Japan approved Temcell® (allogeneic bone marrow mesenchymal stem cells) for the treatment of GvHD. South Korea: In 2022, South Korea approved Cartistem® (umbilical cord blood-derived mesenchymal stem cells) for the treatment of degenerative arthritis. China: In 2024, China’s National Medical Products Administration (NMPA) approved “Aimaituosai Injection” (human umbilical cord mesenchymal stem cell injection) ...
- Source: drugdu
- 108
- April 11, 2025
PHARMCHINA

Organiser: Reed Sinopharm Exhibitions Time: May 21–23, 2025 Address: No. 380, Yuejiang Middle Road, Haizhu District, Guangzhou City Exhibition hall: Canton Fair Complex – Pazhou Hall, Guangzhou Product range: Chemical Pharmaceuticals Proprietary Chinese Medicines (Ethnic Medicines) OTC Drugs Medical Consumables Medical Devices Biotechnology & Innovation (Genetic Testing, Diagnostic Reagents, Pharmaceutical R&D, Contract Customization, Biopharmaceuticals, Biotechnology, Biological Products, etc.) Chinese Herbal Materials/Decoction Pieces (Bulk Decoctions, Traditional Decoctions, Refined Packaged Decoctions, Small-Package Decoctions, Orally Administered Solid Decoctions, Crushed-Wall Decoctions, Chinese Medicine Formula Granules, Novel Decoction Forms, Chinese Herbal Materials, Production Equipment for Decoction Pieces, Packaging for Decoction Pieces, etc.) Moxibustion & Moxa Products Traditional Chinese Medicine (TCM) Wellness (TCM Wellness Centers, Foot Bath/Spa/Herbal Bath Products, TCM Cosmetics, Chinese-Style Medicinal Oils/Balms, Medicinal Diets, Health Tonics, etc.) TCM Diagnostics & Equipment (TCM Diagnostic Devices, TCM Instruments, Traditional Chinese Medicine Processing Equipment, etc.) Internet + Pharmaceuticals (B2B, B2C, O2O E-commerce Platforms, Health Management Platforms, Smart Medicine Cabinets, ...
- Source: drugdu
- 118
- April 10, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.